Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study - Concepedia

Concepedia

Publication | Closed Access

Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study

86

Citations

10

References

2009

Year

Josep Mallolas, Daniel Podzamczer, Ana Milinkovic, Peré Domingo, Bonaventura Clotet, Félix Gutiérrez, Hernando Knobel, J. Cosin, Elena Ferrer, J. A. Arranz,

JAIDS Journal of Acquired Immune Deficiency Syndromes

Abstract

Switching to ATV/r in virologically suppressed patients who were receiving a LPV/r-containing highly active antiretroviral therapy provided comparable (noninferior) efficacy and a safety profile with improved lipid parameters [ISRCTN24813210].

References

	Year	Citations

Page 1